glioma
Conditions
Interventions
Usefulness of using C-11 methionine PET
Sponsors
Hokkaido University Hospital
1.Osaka University Hospital 2.Fukushima Medical University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)The patients whose doctor plans a biopsy or tumor resection and whose tumor is suspected as primary glioma by board-certified diagnostic radiologists and board-certified neurosurgeons based on clinical manifestations, clinical courses, and MRI findings. (2)The patients who or whose legal representative gave a written informed consent to this study.
Exclusion criteria
Exclusion criteria: (1)The patients with a history of allergic reaction to C-11 methionine or F-18 FDG. (2)Pregnant women, breast-feeding women, or women who may be pregnant (3)The patients who is participating in other trials (4)The patients who underwent C-11 methionine PET within 90 days (5)The patients whose overall status is not satisfactory for surgical treatment (6) The patients who cannot undergo contrast-enhanced MRI (7) The patients whom investigators judged to be inadequate as candidates
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive-predictive value (PPV) in the site of negative contrast-enhanced MRI and positive Met-PET which assume a histopathology diagnosis criteria diagnosis. | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Rate of cases where Met-PET positive area is equivalent to MRI enhanced area (2)Rate of cases where tumor exists in the area of MRI-positive and Met-PET-negative findings. (3)Safety: Presence/absence and details of the adverse event, including abnormal changes of vital signs and laboratory data. | — |
Countries
Japan
Contacts
Public ContactEriko Suzuki
Hokkaido University, Graduate School of Medicine Department of Nuclear Medicine
Outcome results
None listed